Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical program supporting the treatment of surgically eligible ...

Oric Pharmaceuticals (NASDAQ:ORIC) detailed new dose-optimization results for its PRC2 inhibitor rinzimetostat and outlined ...

Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.

A study published in the Journal of Bioresources and Bioproducts establishes quantitative structure-activity relationships ...

Merck (NYSE:MRK) received European Union approval for KEYTRUDA in combination regimens for adults with platinum-resistant ...

In Alzheimer’s disease, brain damage is often linked to a mix of problems, including beta-amyloid buildup, tau pathology, ...

Zura Bio (ZURA) stock update: tibulizumab enters Phase 2 for HS/SSc, cash runway to 2028, and key differentiation risks.

Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in ...

Detailed price information for Onco-Innovations Limited (ONCO-NE) from The Globe and Mail including charting and trades.

Brazil Digestive Remedies Market to Reach USD 1.11 Billion by 2032, Says Vyansa Intelligence ...

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...